19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
07:00 , Aug 13, 2015 |  BC Innovations  |  Tools & Techniques

Helping Beethoven hear

Little progress has been made in developing therapies for hearing loss that go beyond the temporary and partial solutions provided by hearing aids and cochlear implants, and most company activity is focused on acquired forms...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

AUT00063: Phase IIa started

Autifony began the double-blind, placebo-controlled, U.K. Phase IIa QUIET-1 trial to evaluate 800 mg oral AUT00063 once daily for 28 days in about 152 patients. Autifony Therapeutics Ltd. , London, U.K.   Product: AUT00063  ...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

AUT00063: Phase I started

Autifony began a placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending-doses of oral AUT00063 in about 60 healthy volunteers. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) spun out Autifony in 2011 to develop...
07:00 , Jun 17, 2013 |  BioCentury  |  Emerging Company Profile

Autifony: Sense and sensitivity

Autifony Therapeutics Ltd. is developing compounds for hearing loss and tinnitus that modulate potassium channel Kv3 , a target on inhibitory receptors of the CNS that may affect central auditory processing of speech and other...